0 647

Cited 11 times in

Effects of ginsenoside Rb1 on hypertrophic scar remodeling in rabbit model.

DC Field Value Language
dc.contributor.author강은혜-
dc.contributor.author노현-
dc.contributor.author유대현-
dc.contributor.author이동원-
dc.contributor.author이명철-
dc.contributor.author탁관철-
dc.date.accessioned2018-03-26T17:11:36Z-
dc.date.available2018-03-26T17:11:36Z-
dc.date.issued2015-
dc.identifier.issn0014-2999-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/157320-
dc.description.abstractGinsenoside, one of the active compounds in Panax ginseng, inhibits tumor growth factor-beta 1 (TGF-β1) and reduces the level of collagen type 1. Ginsenoside Rb1 promotes burn wound healing. Our study evaluated the effects of ginsenoside Rb1 on hypertrophic scar remodeling. A total of 72 hypertrophic scars were generated on the ears of six New Zealand white rabbits. Treatment groups were administered with intradermal injections of ginsenoside Rb1 at various amounts (0.07mg, 0.28mg and 0.56mg), and evaluated on postoperative Day 35. Scar elevation index was used as a quantitative measure, and picrosirius staining of histological sections was used to assess collagen arrangement. We determined relative mRNA expression of collagen type 1 as well as scar related factors; matrix metalloproteinase 2 (MMP2), tissue-inhibitor of metalloproteinase 1 (TIMP1), alpha-smooth muscle actin (α-SMA), and TGF-β1. Immunohistochemistry assays were performed additionally. Application of 0.56mg of ginsenoside Rb1 resulted in significant decrement of scar elevation index, in comparison with control and lower dosage groups, furthermore achieved broader and randomly arranged collagen fibers resembling findings in normal dermis. Ginsenoside Rb1 concentration inversely correlated with the mRNA expression and immunohistochemical reactivity of scar related factors; MMP2, TIMP1, α-SMA, and TGF-β1. In addition, ginsenoside Rb1 suppressed collagen type 1 expression. Ginsenoside Rb1 is therapeutic in hypertrophic scar remodeling with the highest efficacy at 0.56mg of dosage. Ginsenoside Rb1 demonstrated inhibitory effects on hypertrophic scar in quantitative and histologic analysis. Further research is needed to determine optimal ginsenoside Rb1 application and exposure conditions.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science-
dc.relation.isPartOfEUROPEAN JOURNAL OF PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHCicatrix, Hypertrophic/metabolism-
dc.subject.MESHCicatrix, Hypertrophic/pathology-
dc.subject.MESHCicatrix, Hypertrophic/physiopathology*-
dc.subject.MESHCollagen Type I/metabolism-
dc.subject.MESHEar/injuries-
dc.subject.MESHEar/pathology-
dc.subject.MESHEar/physiopathology-
dc.subject.MESHFibrosis-
dc.subject.MESHGinsenosides/pharmacology*-
dc.subject.MESHRabbits-
dc.subject.MESHWound Healing/drug effects*-
dc.titleEffects of ginsenoside Rb1 on hypertrophic scar remodeling in rabbit model.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentYonsei Biomedical Research Center-
dc.contributor.googleauthorKwan Chul Tark-
dc.contributor.googleauthorDong Won Lee-
dc.contributor.googleauthorDae Hyun Lew-
dc.contributor.googleauthorEun Hye Kang-
dc.contributor.googleauthorHyun Roh-
dc.contributor.googleauthorMyung Chul Lee-
dc.identifier.doi10.1016/j.ejphar.2015.01.011-
dc.contributor.localIdA00071-
dc.contributor.localIdA01301-
dc.contributor.localIdA02459-
dc.contributor.localIdA02729-
dc.contributor.localIdA02757-
dc.contributor.localIdA04236-
dc.relation.journalcodeJ00842-
dc.identifier.eissn1879-0712-
dc.identifier.pmid25620132-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0014299915000333-
dc.subject.keywordCollagen type 1-
dc.subject.keywordGinsenoside Rb1-
dc.subject.keywordGinsenoside Rb1 (CID: C442759)-
dc.subject.keywordHypertrophic scar-
dc.subject.keywordProfibrotic factors-
dc.subject.keywordScar elevation index-
dc.contributor.alternativeNameKang, Eun Hye-
dc.contributor.alternativeNameRoh, Hyun-
dc.contributor.alternativeNameLew, Dae Hyun-
dc.contributor.alternativeNameLee, Dong Won-
dc.contributor.alternativeNameLee, Myung Chul-
dc.contributor.alternativeNameTark, Kwan Chul-
dc.contributor.affiliatedAuthorKang, Eun Hye-
dc.contributor.affiliatedAuthorRoh, Hyun-
dc.contributor.affiliatedAuthorLew, Dae Hyun-
dc.contributor.affiliatedAuthorLee, Dong Won-
dc.contributor.affiliatedAuthorLee, Myung Chul-
dc.contributor.affiliatedAuthorTark, Kwan Chul-
dc.citation.volume750-
dc.citation.startPage151-
dc.citation.endPage159-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF PHARMACOLOGY, Vol.750 : 151-159, 2015-
dc.identifier.rimsid42354-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Plastic and Reconstructive Surgery (성형외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.